Erythropoietin: a candidate compound for neuroprotection in schizophrenia

@article{Ehrenreich2004ErythropoietinAC,
  title={Erythropoietin: a candidate compound for neuroprotection in schizophrenia},
  author={Hannelore Ehrenreich and Detlef Degner and Johannes Meller and Michael Brines and Martin P B{\'e}h{\'e} and Martin Hasselblatt and Helge Woldt and Peter G Falkai and Friederike Knerlich and Sonja Jacob and Nicolas von Ahsen and Wolfgang Maier and Wolfgang Br{\"u}ck and Eckart Rüther and Anthony Cerami and Wolfgang Becker and Anna-Leena Sir{\'e}n},
  journal={Molecular Psychiatry},
  year={2004},
  volume={9},
  pages={42-54}
}
Erythropoietin (EPO) is a candidate compound for neuroprotection in human brain disease capable of combating a spectrum of pathophysiological processes operational during the progression of schizophrenic psychosis. The purpose of the present study was to prepare the ground for its application in a first neuroprotective add-on strategy in schizophrenia, aiming at improvement of cognitive brain function as well as prevention/slowing of degenerative processes. Using rodent studies, primary… 
View on Springer
nature.com
195 Citations
Highly Influential Citations
3
Background Citations
73
Methods Citations
8
Results Citations
4

195 Citations

Citation Type

Citation Type

Recombinant Human Erythropoietin: Novel Approach to Neuroprotection and Neuroregeneration in Schizophrenia
TLDR
It is demonstrated that EPO enriched within brain tissue in healthy and even more so in schizophrenic individuals, most likely explained by the higher density of EPOR expression in frontal cortex and hippocampus of the latter, which delayed progressive cortical gray matter loss in schizophrenia-relevant brain areas.
Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition.
TLDR
The "Göttingen-EPO-stroke trial" has provided first promising data on humans for a neuroprotective therapy of an acute brain disease and an exploratory trial in chronic progressive multiple sclerosis yielded first positive results of EPO treatment on both motor function and cognition.
Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia
TLDR
It is shown by voxel-based morphometry in 32 human subjects in a placebo-controlled study that weekly high-dose EPO for as little as 3 months halts the progressive atrophy in brain areas typically affected in schizophrenia, including hippocampus, amygdala, nucleus accumbens, and several neocortical areas.
Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease
TLDR
The “Göttingen EPO-stroke trial” represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a Neuroprotective strategy for a chronic brain disease.
Erythropoietin Enhances Hippocampal Response during Memory Retrieval in Humans
TLDR
Epo increased hippocampus response during picture retrieval compared with placebo, consistent with upregulation of hippocampal BDNF and neurotrophic actions found in animals and highlights Epo as a promising candidate for treatment of psychiatric disorders.
The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease
TLDR
The safety profile and effectiveness of EPO in a wide variety of neurologic disease models make EPO a candidate compound for a potential first-line therapeutic for neurologic emergencies.
Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression
TLDR
Beneficial effects of EPO on hippocampus-dependent memory function and on depression-relevant behavior are demonstrated, highlighting EPO as a candidate agent for future management of cognitive dysfunction and mood symptoms in depression.
Erythropoietin and Non-Erythropoietic Derivatives in Cognition
TLDR
The molecular, cellular and cognitive actions of Epo and non-erythropoietic molecular derivatives are examined by focusing on their neurotrophic, synaptic, myelin plasticity, anti-inflammatory and neurogenic mechanisms in the brain.
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system
Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Erythropoietin – a novel concept for neuroprotection
TLDR
The focus of this review is on a novel neuroprotective approach with erythropoietin, a hematopoietic growth factor that is expressed in the human central nervous system and has demonstrated remarkable neuroprot protective potential in cell culture and animal models of disease.
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
TLDR
Intravenous high-dose rhEPO is well tolerated in acute ischemic stroke and associated with an improvement in clinical outcome at 1 month, and analysis of covariance controlled for these two variables indicated thatrhEPO treatment was associated with a improvement in follow-up and outcome scales.
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
  • M. Brines, P. Ghezzi, A. Cerami
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2000
TLDR
R-Hu-EPO also ameliorates the extent of concussive brain injury, the immune damage in experimental autoimmune encephalomyelitis, and the toxicity of kainate, and clinical trials evaluating systemically administered r-Hu -EPO as a general neuroprotective treatment are warranted.
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
TLDR
In cerebrospinal fluid of drug‐free schizophrenic patients, a significant decrease in the level of total glutathione (GSH) was observed, in keeping with the reported reduced level of its metabolite γ‐glutamylglutamine.
In vivo evidence that erythropoietin protects neurons from ischemic damage.
  • M. Sakanaka, T. Wen, R. Sasaki
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
TLDR
In vivo evidence is reported that EPO protects neurons against ischemia-induced cell death and may exert its neuroprotective effect by reducing the NO-mediated formation of free radicals or antagonizing their toxicity.
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
  • A. Sirén, M. Fratelli, P. Ghezzi
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2001
TLDR
Data suggest that inhibition of neuronal apoptosis underlies short latency protective effects of EPO after cerebral ischemia and other brain injuries, and the neurotrophic actions suggest there may be longer-latency effects as well.
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo
TLDR
Asialoerythropoietic variants of rhEPO can cross the blood–brain barrier and provide neuroprotection, and asialoEPO exhibits a broad spectrum of neuroprotective activities, as demonstrated in models of cerebral ischemia, spinal cord compression, and sciatic nerve crush.
Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production
Neuroprotection – what does it mean? – what means do we have?
Neuroprotection – only a fashionable phrase that has raised hopes and public confidence, particularly among patients affected from neuropsychiatric disease and their relatives? An expression that…
The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave
TLDR
It is concluded that schizophrenia is certainly not a degenerative brain disorder, and it is likely that a brain insult in utero or at birth plays a role in its expression, and current evidence cannot completely exclude the role of environmental variables after birth.
...
1
2
3
4
5
...